The first prospective study to look at this problem since investigators identified an issue earlier confirmed that clinicians ...
Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
Approval was based on improved survival outcomes vs platinum-based chemotherapy as demonstrated in the phase 3 NIAGARA study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback